VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tunica Albuginea who wrote (4418)	1/8/1998 11:18:00 AM
From: Gene Voss	Read Replies (1) of 23519

TA: I refered to this very concern in a recent post.Bias is very easily introduced in a study even when obectivity is a priority.I agree with the contention that company funded research should continue. Financial disclosure would help prevent obvious bias since the investigator would know a conflict of interest is suspected if he has a strong financial tie to the product he is evaluating.It would also encourage him to design a study as devoid of bias as possible since his financial ties are known,he would know his study will be viewed with intense scrutiny. Human evaluation error is always something to be aware of and an honest evaluation the goal.Unfortunately these are difficult times financially in medicine so investigators are under intense pressure to please their benefactors. GV

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next